drugset / Trial / NCT04669067
TL-895 and KRT-232 Study in Acute Myeloid Leukemia
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study evaluates TL-895, a potent, orally available and highly selective irreversible tyrosine kinase inhibitor combined with navtemadlin (KRT-232), a novel oral small molecule inhibitor of MDM2 for the treatment of adults with FLT3 mutated Acute Myeloid Leukemia. Participants must be relapsed/refractory (e.g., having failed prior therapy) to be eligible for this study.
Timeline
- Start
- 2021-03-31
- Primary completion
- 2024-11
- Completion
- 2025-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Navtemadlin | Small molecule | 240 mg | Oral |
| Subject | Navtemadlin | Small molecule | 300 mg | Oral |
| Subject | TL-895 | Small molecule | 150 mg | Oral |
| Subject | TL-895 | Small molecule | 300 mg | Oral |
| Subject | TL-895 | Small molecule | 450 mg | Oral |